Alcon (ALC) Stock Overview
Researches, develops, manufactures, distributes, and sells eye care products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALC Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alcon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 53.28 |
| 52 Week High | CHF 74.34 |
| 52 Week Low | CHF 47.80 |
| Beta | 0.70 |
| 1 Month Change | 0% |
| 3 Month Change | -10.48% |
| 1 Year Change | -23.62% |
| 3 Year Change | -25.63% |
| 5 Year Change | -18.28% |
| Change since IPO | -8.22% |
Recent News & Updates
Narrative Update • Jun 19
ALC: Cataract Platform Expansion And Share Buybacks Will Drive Future Upside
Analysts have trimmed their price target on Alcon, with updated fair value estimates moving from around CHF 79.02 to CHF 76.62 as they adjust assumptions for the discount rate, revenue growth, profit margin and future P/E. What’s in the News for Alcon Alcon launched the UNITY CS cataract surgical system in Canada, described as the company’s next generation standalone cataract platform, with a showcase planned at the Canadian Ophthalmological Society Annual Meeting and Exhibition in June 2026, according to Alcon.
Narrative Update • Jun 04
ALC: Share Buybacks And Patent Royalties Will Shape Measured Forward Outlook
Analysts have adjusted their price target on Alcon to reflect updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, resulting in a revised target of CHF 56.34 compared with the previous CHF 60.81. What's in the News Alcon announced a share repurchase program of up to US$1,500 million, funded by cash generated from operations, with repurchased shares to be cancelled as a return of capital to shareholders; the program is valid for 3 years.
Narrative Update • May 19
ALC: Share Buybacks And New Eye Care Launches Will Support Upside
Analysts now estimate Alcon's fair value at CHF 88.89, reduced from CHF 92.41, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Board of Directors authorized a share repurchase program of up to US$1,500 million.Recent updates
Narrative Update • Jun 19
ALC: Cataract Platform Expansion And Share Buybacks Will Drive Future Upside
Analysts have trimmed their price target on Alcon, with updated fair value estimates moving from around CHF 79.02 to CHF 76.62 as they adjust assumptions for the discount rate, revenue growth, profit margin and future P/E. What’s in the News for Alcon Alcon launched the UNITY CS cataract surgical system in Canada, described as the company’s next generation standalone cataract platform, with a showcase planned at the Canadian Ophthalmological Society Annual Meeting and Exhibition in June 2026, according to Alcon.Narrative Update • Jun 04
ALC: Share Buybacks And Patent Royalties Will Shape Measured Forward Outlook
Analysts have adjusted their price target on Alcon to reflect updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, resulting in a revised target of CHF 56.34 compared with the previous CHF 60.81. What's in the News Alcon announced a share repurchase program of up to US$1,500 million, funded by cash generated from operations, with repurchased shares to be cancelled as a return of capital to shareholders; the program is valid for 3 years.Narrative Update • May 19
ALC: Share Buybacks And New Eye Care Launches Will Support Upside
Analysts now estimate Alcon's fair value at CHF 88.89, reduced from CHF 92.41, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Board of Directors authorized a share repurchase program of up to US$1,500 million.Narrative Update • May 04
ALC: New Eye Care Launches Will Support Future Upside Potential
Analysts have nudged their Alcon price target slightly higher to CHF 92.41 from CHF 92.37, reflecting updated assumptions for revenue growth, profit margin and future P/E that leave the overall valuation framework broadly intact. What's in the News Alcon launched Clareon TruPlus, a new enhanced design monofocal and toric intraocular lens in the U.S., adding to its Clareon IOL portfolio and targeting increased depth of focus while maintaining distance vision quality.Narrative Update • Apr 19
ALC: Contact Lens Expansion And Patent Royalties Will Shape Measured Outlook
Analysts have trimmed their Alcon price target slightly to around CHF61 from about CHF62, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E that are broadly similar to prior estimates. What's in the News Alcon launched Clareon TruPlus monofocal and toric intraocular lenses in the U.S., adding an enhanced design option to the Clareon portfolio that is intended to increase depth of focus while maintaining distance image quality.Narrative Update • Apr 05
ALC: Future Contact Lens Expansion And Patent Royalties Will Shape Balanced Outlook
Analysts have raised their CHF fair value estimate for Alcon from CHF58.49 to CHF61.63, citing updated assumptions that combine a lower future P/E with a higher projected profit margin. What's in the News Sight Sciences reported that a U.S. District Court order in its patent infringement case preserved a jury verdict that Alcon willfully infringed three patents related to the Hydrus Microstent, with monetary damages of $34 million, plus supplemental damages, interest, and an ongoing 10% royalty on Hydrus revenue through November 10, 2028, subject to final judgment and potential appeal (Key Developments).Narrative Update • Mar 22
ALC: New Lens Launches And Share Buybacks Will Support Future Outperformance
Analysts have raised their CHF price target for Alcon by roughly CHF 3, reflecting updated assumptions that combine slightly softer revenue growth with higher profit margins and a lower future P/E multiple. What's in the News Alcon launched TOTAL30 Multifocal for Astigmatism in the U.S., described as the only multifocal toric contact lens with Water Gradient Technology aimed at presbyopic patients with astigmatism (Key Developments).Narrative Update • Mar 08
ALC: Share Repurchases And New Contact Lenses Will Support Upside
Analysts have reduced their Alcon price target to CHF 92.37 from CHF 93.18, reflecting updated views on a slightly higher discount rate, modestly lower revenue growth assumptions, improved profit margin expectations and a lower future P/E multiple. What's in the News Alcon announced the U.S. launch of TOTAL30 Multifocal for Astigmatism, described as the only multifocal toric contact lens with Water Gradient Technology and aimed at patients whose vision needs are shifting toward presbyopia, with lenses now available nationwide through Eye Care Professionals (company announcement).Narrative Update • Feb 22
ALC: Future Contact Lens Launches Will Balance Margin Pressure Risks
Analysts have reduced their price target on Alcon to about CHF 58.50 from roughly CHF 62.30, citing updated assumptions that combine slightly different revenue expectations with lower projected profit margins and a higher future P/E multiple. What's in the News Alcon launched TOTAL30 Multifocal for Astigmatism in the U.S., described as the only multifocal toric contact lens with Water Gradient Technology, aimed at patients whose vision is shifting toward age related presbyopia and who need comfort through a full month of wear (Key Developments).Narrative Update • Feb 08
ALC: Weekly Lens Launch And Buybacks Will Support Future Share Outperformance
Analysts have trimmed their price target for Alcon to approximately $75.68 from about $79.76, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Alcon plans a Canadian launch of PRECISION7 sphere and toric one week replacement contact lenses featuring the ACTIV-FLO System, designed to provide 16 hours of comfort and consistent vision through day 7, with commercial availability expected from February 2, 2026 (Key Developments).Narrative Update • Jan 24
ALC: Ongoing Share Repurchases And Higher Future P/E Will Support Upside
Analysts have modestly trimmed their price target on Alcon by about US$1 to reflect slight adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall view largely intact. What's in the News Alcon completed a share repurchase of 9,301,877 shares, representing 1.89% of its shares, for US$750 million under the buyback announced on February 25, 2025.Narrative Update • Jan 09
ALC: Share Repurchases And Higher P/E Assumptions Will Support Future Upside
Analysts have nudged their price target on Alcon higher by roughly US$0.26, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers behind the revision. What's in the News Alcon reported impairments of property, plant and equipment and intangible assets of US$2 million for the quarter ended September 30, 2025 (Key Developments).Narrative Update • Dec 25
ALC: Improved Margins And Buybacks Will Support Stronger Share Performance
Analysts have modestly reduced their price target on Alcon, citing slightly slower projected revenue growth and a higher discount rate that outweigh the benefit of improved margin expectations and a lower future price to earnings multiple. This brings their fair value estimate down by approximately 4.40 dollars per share.Narrative Update • Dec 11
ALC: Future Surgical Efficiency Gains Will Support Share Outperformance
Analysts have slightly reduced their price target on Alcon to reflect a modestly lower fair value estimate of approximately $79.76. This adjustment comes even as projected revenue growth has been revised marginally higher, because that improvement is offset by a slightly reduced profit margin and an almost unchanged future price-to-earnings multiple.Narrative Update • Nov 27
ALC: Surgical Workflow Gains Will Drive Share Outperformance In Coming Quarters
Alcon's analyst price target has been raised slightly from $79.92 to $80.15, with analysts citing minor adjustments to revenue growth and profit margin assumptions as the primary drivers of this upward revision. What's in the News Alcon announced $2 million in impairments of property, plant and equipment, and intangible assets for the quarter ending September 30, 2025.Analysis Article • Nov 14
Alcon Inc. (VTX:ALC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Alcon Inc. ( VTX:ALC ) had a good week, as its shares rose 5.9% to close at CHF62.88 following the release...Narrative Update • Nov 12
ALC: Surgical Efficiency Gains Will Drive Share Momentum Ahead
Narrative Update: Alcon Analyst Price Target Revision Analysts have raised their price target for Alcon from $79.17 to $79.92. This revision is based on updated valuation models that reflect modest adjustments in discount rates and forward profit expectations.Narrative Update • Oct 27
Cutting Edge Eye Care Solutions Will Transform Outcomes For Global Aging Populations
Alcon's analyst price target has been revised slightly downward, decreasing by $1.25 to $79.17. Analysts have adjusted their expectations to reflect slightly lower revenue growth and profit margin forecasts.Narrative Update • Oct 13
Global Aging And Emerging Markets Will Expand Eye Care
Analysts have slightly reduced their price target for Alcon from $81.30 to $80.43, citing cautious adjustments to growth and profit margin expectations. What's in the News Alcon announced results from multiple time and motion studies showing its UNITY Vitreoretinal Cataract System (VCS) achieves up to 16% efficiency gain in workflow compared to other leading vision systems, with significant reductions in setup and tear-down times.Narrative Update • Aug 23
Unity VCS And PRECISION7 Launches Will Strengthen Position In Eye Care Market
Alcon's consensus price target has been revised downward, primarily reflecting a significantly lower future P/E multiple despite improved revenue growth forecasts, resulting in a new fair value estimate of CHF82.40. What's in the News Alcon updated 2025 net sales guidance to $10.3–$10.4 billion, slightly down from the previous $10.4–$10.5 billion, while reaffirming Core diluted EPS at $3.05–$3.15.Analysis Article • Aug 14
Is Now The Time To Put Alcon (VTX:ALC) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Jul 02
Earnings Tell The Story For Alcon Inc. (VTX:ALC)
With a price-to-earnings (or "P/E") ratio of 39.5x Alcon Inc. ( VTX:ALC ) may be sending very bearish signals at the...
New Narrative • Mar 19
Unity VCS And PRECISION7 Launches Will Strengthen Position In Eye Care Market
Alcon's broad product pipeline and innovations in Surgical, Vision Care, and Ocular Health are positioned to propel revenue growth.Shareholder Returns
| ALC | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 1.4% | 1.8% | 0.9% |
| 1Y | -23.6% | -15.6% | 15.2% |
Return vs Industry: ALC underperformed the Swiss Medical Equipment industry which returned -15.6% over the past year.
Return vs Market: ALC underperformed the Swiss Market which returned 15.2% over the past year.
Price Volatility
| ALC volatility | |
|---|---|
| ALC Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: ALC has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: ALC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 25,000 | David Endicott | www.alcon.com |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures.
Alcon Inc. Fundamentals Summary
| ALC fundamental statistics | |
|---|---|
| Market cap | CHF 25.74b |
| Earnings (TTM) | CHF 663.43m |
| Revenue (TTM) | CHF 8.61b |
39.2x
P/E Ratio3.0x
P/S RatioIs ALC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALC income statement (TTM) | |
|---|---|
| Revenue | US$10.63b |
| Cost of Revenue | US$4.66b |
| Gross Profit | US$5.97b |
| Other Expenses | US$5.15b |
| Earnings | US$819.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 11, 2026
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 56.14% |
| Net Profit Margin | 7.70% |
| Debt/Equity Ratio | 21.4% |
How did ALC perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield21%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/23 00:04 |
| End of Day Share Price | 2026/06/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alcon Inc. is covered by 58 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| null null | Baird |
| Jeffrey Johnson | Baird |